HEMARNA™
Targets 232 fusion genes in hematolymphoid tumors
Hematolymphoid tumors are a group of highly heterogeneous diseases. So far, more than 100 fusion genes have been introduced in the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Fusion gene testing is crucial in diagnosis, treatment decision making, MRD monitoring and prognosis.
WHO IS IT FOR
- Early fusion screening for patients with hematolymphoid tumors (including acute lymphoblastic lymphoma, acute myeloid leukaemia, myeloproliferative neoplasms, and lymphomas)
- Patients with hematolymphoid tumors but are ‘pan-negative’ or have non-classical fusions and require further fusion testing
- Patients with specific fusion mutations undergoing dynamic monitoring after treatment or relapse
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and cerebrospinal fluid)
Peripheral blood or bone marrow
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
